PI
Cancer Center Amsterdam
-
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
Tettero, J. M., Buisman, Y., Ngai, L. L., Bachas, C., Gjertsen, B. T., Kelder, A., van de Loosdrecht, A. A., Manz, M. G., Pabst, T., Scholten, W., Ossenkoppele, G. J., Cloos, J. & de Leeuw, D. C., 21 Dec 2023, In: HemaSphere. 7, 12, p. E981Research output: Contribution to journal › Article › Academic › peer-review
-
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK), 1 Dec 2023, In: Blood Cancer Journal. 13, 1, 93.Research output: Contribution to journal › Article › Academic › peer-review
-
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Ravandi, F., Cloos, J., Buccisano, F., Dillon, R., Döhner, K., Freeman, S. D., Hourigan, C. S., Ossenkoppele, G. J., Roboz, G. J., Subklewe, M., Thiede, C., Arnhardt, I., Valk, P. J. M., Venditti, A., Wei, A. H., Walter, R. B. & Heuser, M., Dec 2023, In: American journal of hematology. 98, 12, p. 1847-1855 9 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications